Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis. Issue 11 (2nd November 2015)

• Record Type: Journal Article
• Authors: Ye, Yongbin; Xu, Xiaojun; Zhang, Mingwan; Qiu, Dafa; Bai, Xiaochun; Wang, Jing; Weng, Guangyang; Zhou, Ruiqing; Guo, Ziwen; He, Huiqing; Yi, Wenfang; He, Xin; Guo, Kunyuan
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 11(2015:Nov.)
• Page Start: 3159
• Page End: 3167
• Publication Date: 2015-11-02
• Subjects: Arsenic trioxide -- aclacinomycin A -- apoptosis -- cytotoxic effect -- acute myeloid leukemia; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1011155
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract : Acute myeloid leukemia (AML) is a common disorder in the elderly. Although remarkable progress has been made over recent decades, the outcome remains poor. Thus, the development of a more effective method to overcome this problem is necessary. In this study, we aimed to investigate the synergistic cytotoxic effect of low-dose arsenic trioxide (As2 O3 ) combined with aclacinomycin A (ACM) on the human AML cell lines KG-1a and HL-60, and to clarify the underlying mechanism. Results showed that As2 O3 combined with ACM exerted a synergistic cytotoxic effect by activation of the apoptosis pathway. Additionally, we found that the combination treatment decreased Bcl-2, c-IAP and XIAP expression but increased SMAC and caspase-3 expression more significantly than the single drug treatments. Furthermore, combination index (CI) values were < 1 in all matched combination groups. Additional evaluation of As2 O3 combined with ACM as a potential therapeutic benefit for AML seems warranted.